[Levels of plasma endothelin, nitric oxide and atrial natriuretic peptide after cardiopulmonary bypass and influence of inhaled nitric oxide in patients with ventricular septal defect and pulmonary hypertension]

What Was Tested

Researchers studied ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.

To assess the changes of the levels of plasma endothelin (ET-1), nitric oxide (NO) and atrial natriuretic peptide (ANP) after cardiopulmonary bypass (CPB) and the influence of inhaled nitric oxide in patients with ventricular septal defect (VSD) and pulmonary hypertension (PH).

Who Took Part

By PubMed's age tags, the people studied were young children, both men and women.

Sixty patients with VSD were enrolled in this study.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

Group B was subdivided into two groups by randomized block, group B(1) (inhaled NO group, n = 20) and group B(2) (contrast group, n = 20).

The plasma ET-1, NO, ANP concentrations were assayed at 24 h pre-operation and 0 h, 1 h, 5 h, 12 h, 24 h, 48 h after CPB.

What Was Measured

PubMed files the paper under topics including Administration, Inhalation, Atrial Natriuretic Factor, Cardiopulmonary Bypass, Endothelin-1, Heart Septal Defects, Hypertension, Pulmonary and Nitric Oxide.

What This Means in Plain Language

The paper is a randomized study of ANP (Atrial Natriuretic Peptide).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (Zhonghua wai ke za zhi [Chinese journal of surgery]), a journal based in China.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.